After clinical progression, he was treated with sorafenib, a multiprotein kinase inhibitor more commonly used in the treatment of hepatocellular and renal cell carcinoma due to its off target FLT3 inhibition. The gene discussed is FLT3; the disease is hereditary clear cell renal cell carcinoma.